Xarelto data confirms RECORD results

Bayer HealthCare has published results from the first real-world study of Xarelto (rivaroxaban) which reaffirms the benefits of the once-daily oral anticoagulant in everyday clinical practice.

Findings from the international XAMOS study support the clinical outcomes from the previous RECORD trial which showed Xarelto to have consistently superior efficacy as well as a comparable safety profile to enoxaparin.

Luis Felipe Graterol, Medical Director, Bayer HealthCare UK, says the data delivers “further confidence to prescribers with regards to the clinical potential of Xarelto”.

The drug was recently recommended in final draft guidance by NICE as an option for the prevention of stroke and systemic embolism in people with atrial fibrillation (AF).

The XAMOS study, which included 17,413 patients receiving the treatment or conventional pharmacological treatments for the prevention of blood clots, compared outcomes observed in everyday clinical practice.

The main outcomes of the trial included the incidence of symptomatic thromboembolic events being significantly lower in patients treated with rivaroxaban compared with conventional therapy. Importantly, low and similar rates of major bleeding were also observed.

Dr A.G.G. Turpie, Professor of Medicine, McMaster University, Canada and Chairman of the XAMOS Executive Steering Committee, commented: “As the first and only reported everyday clinical experience of an oral anticoagulant, XAMOS offers real-world evidence that rivaroxaban is effective in protecting against blood clots in the orthopaedic setting.”